These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11397126)

  • 1. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
    Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precursor frequency analysis of bryostatin activated lymphocytes.
    Fleming MD; Barrett SK; Bear HD
    J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
    Miller CH; Graham L; Bear HD
    BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
    Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z; Fan H; Wu Y; Chen B
    Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of murine cytomegalovirus-immune lymph node cells prevents retinitis in T-cell-depleted mice.
    Lu Y; Bigger JE; Thomas CA; Atherton SS
    Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):301-10. PubMed ID: 9040462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.